Related Experiment Video
Updated: Apr 3, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.9K
Emerging and future therapies for hemophilia
Marcus E Carr1, Bartholomew J Tortella2
1Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA ; Worldwide Research and Development, Pfizer, Inc., Cambridge, MA, USA.
Journal of Blood Medicine
|September 15, 2015
Summary
Advances in hemophilia treatment, including enhanced half-life clotting factors, have improved patient lives. Future research focuses on new administration methods, antibody treatments, and gene therapy for a potential cure.
Area of Science:
- Hematology
- Genetic Disorders
- Biotechnology
Background:
- Hemophilia care has significantly advanced over 60 years.
- Key developments include protein purification, recombinant production, and viral inactivation.
- Recent innovations focus on enhanced half-life (EHL) clotting factors for improved prophylaxis.
Purpose of the Study:
- To review the evolution of hemophilia care.
- To summarize data on EHL clotting factors.
- To introduce novel treatment agents and gene therapy efforts.
Main Methods:
- Review of scientific literature on hemophilia treatment advances.
- Analysis of data concerning enhanced half-life clotting factors.
- Compilation of information on emerging therapeutic strategies and gene therapy.
Main Results:
- Significant improvements in hemophilia treatment and patient quality of life.
- Development of EHL clotting factors reducing infusion frequency.
- Identification of ongoing research in alternative therapies and gene therapy.
Conclusions:
- Hemophilia treatment has evolved dramatically, with EHL factors offering improved prophylaxis.
- Unmet needs include alternative administration, treatment for inhibitors, and a definitive cure.
- Gene therapy represents a promising avenue for a potential cure for hemophilia.
Keywords:
anti-tissue factor pathway inhibitor antibodiesclotting factor analogsextended half-life clotting factorsgene therapynonfactor replacement therapyMore Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:29Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K